Meeting
2020 ASCO Virtual Scientific Program
FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
Authors
Amir Iravani
Peter MacCallum Cancer Centre, Melbourne, Australia
Amir Iravani , Roslyn Wallace , Serigne Lo , Anna Galligan , Alison Weppler , George Au-Yeung , Damien Kee , Peter Kar Han Lau , Benjamin M Brady , Belinda Lee , Grant A. McArthur , Shahneen Kaur Sandhu , Rodney J. Hicks
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10041)
DOI
10.1200/JCO.2020.38.15_suppl.10041
Abstract #
10041
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla